Top

Acta Diabetologica

Published in:

01-04-2016 | Original Article

Low levels of ficolin-3 are associated with diabetic peripheral neuropathy

Authors: Xiaoyan Zhang, Yanyun Hu, Jing Shen, Hui Zeng, Junxi Lu, Lianxi Li, Yuqian Bao, Fang Liu, Weiping Jia

Published in: Acta Diabetologica | Issue 2/2016

Abstract

Aims

Ficolin-3, a soluble molecule of the innate immune system, has a primary role in the activation of the lectin pathway in the complement system. Considering that inflammatory mechanisms are involved in complement activation and take part in the pathophysiology of diabetic peripheral neuropathy (DPN), we conducted this study to explore the link between serum ficolin-3 and DPN in diabetic patients.

Methods

A total of 466 diabetic patients were enrolled in this cross-sectional study. DPN was evaluated by neurological symptoms, neurological signs, neurothesiometer and electromyogram. The concentration of serum ficolin-3 was determined by enzyme-linked immunosorbent assay.

Results

The concentration of serum ficolin-3 was lower in DPN patients compared with non-DPN patients (18.73 ± 4.75 vs. 26.69 ± 5.68 ng/mL, P < 0.001). In addition, it was found negatively correlated to the vibration perception threshold (r = −0.158; P = 0.025). The results of multiple regression analysis of DPN indicated that age, diabetes duration, serum ficolin-3 were all independent impact factors for DPN (P < 0.05). Patients were then assigned into quartiles according to the serum ficolin-3 levels, and the prevalence of DPN ascended as the concentration of ficolin-3 descended (Trend analysis, P < 0.001). Compared with ficolin-3 Quartile 1 (referent), the risk of DPN was significantly greater in Quartile 2 (OR 2.76; 95 % CI 1.56–4.88; P < 0.001), Quartile 3 (OR 3.02; 95 % CI 1.69–5.40; P < 0.001) and Quartile 4 (OR 6.84; 95 % CI 3.39–13.80; P < 0.001).

Conclusions

Lower ficolin-3 level is independently associated with DPN, and it may be a potential biomarker for DPN.

Li J, Zhang H, Xie M, Yan L, Chen J, Wang H (2013) NSE, a potential biomarker, is closely connected to diabetic peripheral neuropathy. Diabetes Care 36:3405–3410CrossRefPubMedPubMedCentral

Zychowska M, Rojewska E, Przewlocka B, Mika J (2013) Mechanisms and pharmacology of diabetic neuropathy-experimental and clinical studies. Pharmacol Rep 65:1601–1610CrossRefPubMed

Morano S, Tiberti C, Cristina G, Sensi M, Cipriani R, Guidobaldi L et al (1999) Autoimmune markers and neurological complications in non-insulin-dependent diabetes mellitus. Hum Immunol 60:848–854CrossRefPubMed

Mika J, Osikowicz M, Rojewska E, Korostynski M, Wawrzczak-Bargiela A, Przewlocki R et al (2009) Differential activation of spinal microglial and astroglial cells in a mouse model of peripheral neuropathic pain. Eur J Pharmacol 623:65–72CrossRefPubMed

Collins MP, Periquet-Collins I, Sahenk Z, Killel JT (2010) Direct immunofluoresence in vasculitic neuropathy: specificity of vascular immune deposits. Muscle Nerve 42:62–69CrossRefPubMed

Walport MJ (2001) Complement: first of two parts. N Engl J Med 344:1058–1066CrossRefPubMed

Walport MJ (2001) Complement: second of two parts. N Engl J Med 344:1140–1144CrossRefPubMed

Garred P, Honoré C, Ma YJ, Munthe-Fog L, Hummelshøj T (2009). MBL2, FCN1, FCN2 and FCN3-The genes behind the initiation of the lectin pathway of complement. Mol Immunol 46:2737–2744

Ma YJ, Skjoedt MO, Garred P (2013) Collectin-11/MASP complex formation triggers activation of the lectin complement pathway—the fifth lectin pathway initiation complex. J Innate Immun 5:242–250CrossRefPubMed

10.

Munthe-Fog L, Hummelshoj T, Ma YJ, Hansen BE, Koch C, Madsen HO et al (2008) Characterization of a polymorphism in the coding sequence of FCN3 resulting in a Ficolin-3 (Hakata antigen) deficiency state. Mol Immunol 45:2660–2666CrossRefPubMed

11.

Hein E, Honoré C, Skjoedt MO, Munthe-Fog L, Hummelshøj T, Garred P (2010) Functional analysis of ficolin-3 mediated complement activation. PLoS ONE 5:e15443CrossRefPubMedPubMedCentral

12.

Chen H, Lu J, Chen X, Yu H, Zhang L, Bao Y et al (2012) Low serum levels of the innate immune component ficolin-3 is associated with insulin resistance and predicts the development of type 2 diabetes. J Mol Cell Biol 4:256–257CrossRefPubMed

13.

Rosoklija GB, Dwork AJ, Younger DS, Karlikaya G, Latov N, Hays AP (2000) Local activation of the complement system in endoneurial microvessels of diabetic neuropathy. Acta Nenropathol 99:55–62CrossRef

14.

American Diabetes Association (2014) Standards of medical care in diabetes—2014. Diabetes Care 37(Suppl 1):S14–S80

15.

Ziegler D, Hanefeld M, Ruhnau KJ, Meißner HP, Lobisch M, Schütte K et al (1995) the ALADIN Study Group: treatment of symptomatic diabetic peripheral neuropathy with the anti-oxidant α-lipoic acid: a 3-week multicentre randomized controlled trial (ALADIN Study). Diabetologia 38:1425–1433CrossRefPubMed

16.

Apelqvist J, Bakker K, van Houtum WH, Schaper NC (2008) International Working Group on the Diabetic Foot (IWGDF) Editorial Board. Practical guidelines on the management and prevention of the diabetic foot: based upon the International Consensus on the Diabetic Foot (2007) Prepared by the International Working Group on the Diabetic Foot. Diabetes Metab Res Rev 24(Suppl 1):S181–S187

17.

Shen J, Hu Y, Liu F, Zeng H, Li L, Zhao J et al (2013) Vibration perception threshold for sight-threatening retinopathy screening in type 2 diabetic outpatients. Diabetes Metab Res Rev 29:525–531PubMed

18.

Xiaofu T (1995) Clinical EMG study. The Beijing University of Science and Technology China harmony Medical College unites the publishing house, Beijing

19.

Dyck PJ (1988) Detection, characterization, and staging of polyneuropathy: assessed in diabetics. Muscle Nerve 11:21–32CrossRefPubMed

20.

Wilkinson CP, Ferris FL 3rd, Klein RE, Lee PP, Agardh CD, Davis M et al (2003) Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. Ophthalmology 110:1677–1682CrossRefPubMed

21.

Mythili A, Kumar KD, Subrahmanyam KA, Venkateswarlu K, Butchi RGA (2010) Comparative study of examination scores and quantitative sensory testing in diagnosis of diabetic polyneuropathy. Int J Diabetes Dev Ctries 30:43–48CrossRefPubMedPubMedCentral

22.

Young MJ, Breddy JL, Veves A, Boulton AJ (1994) The prediction of diabetic neuropathic foot ulceration using vibration perception thresholds. A prospective study. Diabetes Care 17:557–560CrossRefPubMed

23.

Shen J, Liu F, Zeng H, Wang J, Zhao JG, Zhao J et al (2012) Vibrating perception threshold and body mass index are associated with abnormal foot plantar pressure in type 2 diabetes outpatients. Diabetes Technol Ther 14:1053–1059CrossRefPubMedPubMedCentral

24.

Prohászka Z, Munthe-Fog L, Ueland T, Gombos T, Yndestad A, Förhécz Z et al (2013) Association of ficolin-3 with severity and outcome of chronic heart failure. PLoS ONE 8:e60976CrossRefPubMedPubMedCentral

25.

Füst G, Munthe-Fog L, Illes Z, Széplaki G, Molnar T, Pusch G et al (2011) Low ficolin-3 levels in early follow-up serum samples are associated with the severity and unfavorable outcome of acute ischemic stroke. J Neuroinflammation 8:185CrossRefPubMedPubMedCentral

26.

Halmos A, Rigó J Jr, Szijártó J, Füst G, Prohászka Z, Molvarec A (2012) Circulating ficolin-2 and ficolin-3 in normal pregnancy and pre-eclampsia. Clin ExpImmunol 169:49–56

27.

Fujita T, Hemmi S, Kajiwara M, Yabuki M, Fuke Y, Satomura A et al (2013) Complement-mediated chronic inflammation is associated with diabetic microvascular complication. Diabetes Metab Res Rev 29:220–226CrossRefPubMed

28.

Kim HJ, Cho EH, Yoo JH, Kim PK, Shin JS, Kim MR et al (2007) Proteome analysis of serum from type 2 diabetics with nephropathy. J Proteome Res 6:735–743CrossRefPubMed

29.

Zheng B, Li T, Chen H, Xu X, Zheng Z (2011) Correlation between ficolin-3 and vascular endothelial growth factor-to-pigment epithelium-derived factor ratio in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol 152:1039–1043CrossRefPubMed

30.

Duchen LW, Anjorin MB, Watkins MD, Mackay MB (1980) Pathology of autonomic neuropathy in diabetes mellitus. Ann Intern Med 92:301–303CrossRefPubMed

31.

Graham AR, Johnson PC (1985) Direct immunofluorescence findings in peripheral nerve from patients with diabetic neuropathy. Ann Neurol 17:450–454CrossRefPubMed

32.

Qin X, Goldfine A, Krumrei N, Grubissich L, Acosta J, Chorev M et al (2004) Glycation inactivation of the complement regulatory protein CD59: a possible role in the pathogenesis of the vascular complications of human diabetes. Diabetes 53:2653–2661CrossRefPubMed

Title: Low levels of ficolin-3 are associated with diabetic peripheral neuropathy
Authors: Xiaoyan Zhang
Yanyun Hu
Jing Shen
Hui Zeng
Junxi Lu
Lianxi Li
Yuqian Bao
Fang Liu
Weiping Jia
Publication date: 01-04-2016
Publisher: Springer Milan
Published in: Acta Diabetologica / Issue 2/2016
Print ISSN: 0940-5429
Electronic ISSN: 1432-5233
DOI: https://doi.org/10.1007/s00592-015-0780-6

ACC 2024 Congress Coverage

Heart Failure Video

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Low levels of ficolin-3 are associated with diabetic peripheral neuropathy

Abstract

Aims

Methods

Results

Conclusions

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Aims

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 2/2016

G protein-coupled receptors: signalling and regulation by lipid agonists for improved glucose homoeostasis

Single patient in GCK-MODY family successfully re-diagnosed into GCK-PNDM through targeted next-generation sequencing technology

Measuring glomerular filtration rate by iohexol clearance on filter paper is feasible in adolescents with type 1 diabetes in the ambulatory setting

Polypharmacy in elderly patients with type 2 diabetes receiving oral antidiabetic treatment

“First, know thyself”: cognition and error in medicine

Trained breathing-induced oxygenation acutely reverses cardiovascular autonomic dysfunction in patients with type 2 diabetes and renal disease

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page